Login to Your Account

Pharma: Clinic Roundup

Tuesday, March 13, 2012
• Pfizer Inc., of New York, said data from a Phase III study of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) met all endpoints, showing immunogenicity and establishing a safety profile in children and adolescents, ages 5 through 17.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription